Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by FORTEPIANI, L. A.
Right arrow Articles by GARCÍA-ESTAÑ, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FORTEPIANI, L. A.
Right arrow Articles by GARCÍA-ESTAÑ, J.
J Am Soc Nephrol 10:21-27, 1999
© 1999 American Society of Nephrology

REGULAR ARTICLES

Pressure Natriuresis in Nitric Oxide-Deficient Hypertensive Rats

Effect of Antihypertensive Treatments

LOURDES A. FORTEPIANI*, ELENA RODRIGO{dagger}, M. CLARA ORTÍZ*, VICTORIA CACHOFEIRO{dagger}, NOEMÍ M. ATUCHA*, LUIS M. RUILOPE{dagger}, VICENTE LAHERA{dagger} and JOAQUÍN GARCÍA-ESTAÑ*

* Departamentos de Fisiología, Facultades de Medicina, Murcia, Spain.
{dagger} Departamentos de Fisiología, Facultades de Medicina, Madrid, Spain.

Correspondence to Dr. Joaquín García-Estañ, Departamento de Fisiología, Facultad de Medicina, 30100 Murcia, Spain. Phone: 34-968-364880; Fax: 34-968-364150; E-mail: jgel{at}fcu.um.es

Abstract. Chronic inhibition of nitric oxide (NO) synthesis has been shown to result in arterial hypertension and an important blunting of the pressure diuresis and natriuresis response (PDN). The mechanisms mediating these abnormalities are not completely understood. In the present study, the role of several antihypertensive drugs to ameliorate these alterations was evaluated. The PDN relationships have been evaluated in rats chronically (8 wk) treated with the NO synthesis inhibitor NG-nitro-L-arginine methyl ester (L-NAME; 40 mg/kg per d in the drinking water). Appropriate groups of rats were simultaneously treated with the angiotensin II receptor blocker candesartan at a low (1.5 mg/kg per d) and high (2.5 mg/kg per d) dose, with the converting enzyme inhibitor captopril (60 mg/kg per d) and with the calcium channel blocker verapamil (100 mg/kg per d). Chronic treatment with L-NAME significantly elevated mean BP (163.6 ± 6.5 mmHg versus 105.1 ± 3.6 in controls), reduced GFR and renal blood flow (RBF), and shifted to the right the PDN responses. Chronic administration of low-dose candesartan, captopril, or verapamil prevented the arterial hypertension and improved renal hemodynamics, but these levels were not completely normalized. High-dose administration also improved renal hemodynamics but induced reduced BP below the levels of control animals. Despite the normalization of the elevated BP, the PDN responses of these hypertensive treated groups were not normalized, and the slopes of the respective diuretic or natriuretic responses were very similar to those of the hypertensive untreated rats. The results indicate that interruption or blockade of the reninangiotensin system and calcium channel blockade are effective treatments for the NO-deficient arterial hypertension and renal vasoconstriction. However, the PDN responses are not normalized, and this finding suggests that the antihypertensive treatment is not enough to overcome the renal alterations associated with the chronic deficiency of NO.




This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
F. Vargas, J. M. Moreno, R. Wangensteen, I. Rodriguez-Gomez, and J. Garcia-Estan
The endocrine system in chronic nitric oxide deficiency
Eur. J. Endocrinol., January 1, 2007; 156(1): 1 - 12.
[Abstract] [Full Text] [PDF]

Home page
 Exp PhysiolHome page
J. Sainz, A. Osuna, R. Wangensteen, J. de Dios Luna, I. Rodriguez-Gomez, J. Duarte, J. M. Moreno, and F. Vargas
Role of sex, gonadectomy and sex hormones in the development of nitric oxide inhibition-induced hypertension
Exp Physiol, March 1, 2004; 89(2): 155 - 162.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
L. A. Fortepiani, M. C. O. Ruiz, F. Passardi, M. D. Bentley, J. Garcia-Estan, E. L. Ritman, and J. C. Romero
Effect of losartan on renal microvasculature during chronic inhibition of nitric oxide visualized by micro-CT
Am J Physiol Renal Physiol, November 1, 2003; 285(5): F852 - F860.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. Obst, V. Gross, J. Janke, M. Wellner, W. Schneider, and F. C. Luft
Pressure Natriuresis in AT2 Receptor-Deficient Mice with L-NAME Hypertension
J. Am. Soc. Nephrol., February 1, 2003; 14(2): 303 - 310.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
E. SEELIGER, P. B. PERSSON, W. BOEMKE, G. MOLLENHAUER, B. NAFZ, and H. W. REINHARDT
Low-Dose Nitric Oxide Inhibition Produces a Negative Sodium Balance in Conscious Dogs
J. Am. Soc. Nephrol., June 1, 2001; 12(6): 1128 - 1136.
[Abstract] [Full Text]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673